FIGURE 2 from EZH2 Inhibition Promotes Tumor Immunogenicity in Lung Squamous Cell Carcinomas

EZH2 inhibition allows upregulation of MHCI and MHCII in human LSCC PDTs. A, H&E staining of primary squamous cell carcinoma tissue, xenograft tissue from primary patient tissue, and tumoroids generated from xenografts, scale bars = 100 µm. B, qRT-PCR in two unique PDT cultures treated for 11 days with 5 µmol/L EZH2 inhibition with 20 ng/mL IFNγ added on day 9 for the genes HLA-A, B2M, CIITA, and HLA-DRA; mean ± SEM is graphed; n = 4; *, P < 0.03; **, P < 0.005; ***, P < 0.0008; ****, P < 0.0001 by one-way ANOVA with multiple comparisons and Holm-Šídák post hoc test. C, Flow cytometry analysis of both PDTs treated for 11 days with 5 µmol/L EZH2 inhibition with 20 ng/mL IFNγ added in on day 9 for cell surface proteins HLA-A,B,C and HLA-DR; mean ± SEM is graphed; n = 4 biological replicates; *, P = 0.043; **, P < 0.004; ***, P < 0.0009; ****, P < 0.0001 by one-way ANOVA with multiple comparisons and Holm-Šídák post hoc test. Representative histograms for Patient 1 are shown, G = GSK126, E = EPZ6438, I = IFNγ, I+G = IFNγ+GSK126, and I+E = IFNγ+EPZ6438. See also Supplementary Fig. S2.